State of children's medicines in the EU
Yesterday, the Commission presented a report to the European Parliament and the Council, on progress made in children's medicines since the Paediatric Regulation came into force 10 years ago.
Yesterday, the Commission presents a report to the European Parliament and the Council, on progress made in children's medicines since the Paediatric Regulation came into force 10 years ago. It concludes that positive advances in the development of medicines for children could not have been achieved without specific EU legislation – e.g. the authorisation of 260 new medicines. The Paediatric Regulation also gives a good return on investment. However, the report acknowledges that more effort is needed to combine the effects of the Paediatric with those of the Orphan medicines Regulation to address shortcomings in treating rare diseases in children.
Commenting on the report, Vytenis Andriukaitis, Commissioner for Health and Food Safety, said: "Whereas I am pleased with the overall progress made in improving children's access to safe, tailored medicines, I am committed to extending these positive gains to children with rare diseases. When we consider the advances in adult oncology, it upsets me deeply that we have not made the same progress in treating the cancers that affect children. In the next 10 years we must focus on making similar breakthroughs for children, by combining the incentives under the Orphans and the Paediatric Regulations, and by ensuring that the European Reference Networks - in particular 'ERN PaedCan' on paediatric cancer, reach full capacity".
- The number of agreed paediatric investigation plans (PIPs) – the first step in developing medicines for children, surpassed 1 000 in 2017. Of these, 131 were completed by the end of 2016.
- There is a clear upward trend in the number of completed PIPs, with over 60 % finalised in the last three years.
- The conditions with the highest number of completed PIPs are immunology/rheumatology (14 %), infectious diseases (14 %), cardiovascular diseases and vaccines (each 10 %).
- Due to the Regulation there has been a significant surge in new treatments for children with rheumatologic diseases, and area where there were very limited therapeutic options before 2007.
- Oncology (childhood cancer) is at the lower end of the agreed paediatric investigation plans, representing only 7% of completed PIPs.
- The report shows that the Regulation works best in areas where the needs of adult and paediatric patients overlap.
- There is also more research into paediatric medicines. The proportion of clinical trials that include children increased by 50 % between 2007 and 2016 from 8.25 % to 12.4 %, leading to more evidence-based information when medicines are used in children.
As an integral part of its assessment of the impact of the Paediatric Regulation, the Commission held a targeted stakeholder consultation which ran from November 2016 to February 2017. Following its adoption, Commissioner Andriukaitis will present the report's findings to people working in regulatory affairs, patients' groups and other stakeholders at a conference in Brussels on 21 November 2017.
This report is an essential intermediate step in the debate on a joint vision about the future parameters for paediatric and orphan medicines. Before proposing any amendments, the Commission will evaluate – in consultation with stakeholders and experts, how the combined effects of the Orphan and Paediatric Regulation can support medicine development in subpopulations of particular need, e.g. children with cancer. Results of this reflection will be presented by 2019 to allow the next Commission to take informed decision about possible policy options.
Follow us on Twitter: @EU_Health
 A Paediatric Investigation Plan (PIP) is a research and development programme that aims to ensure that a new product is tested for its potential use in children and that such tests become an integral part of the overall product development.
Latest News from
Remarks by Commissioner Olivér Várhelyi on the first deliveries of EU funded vaccines for the Western Balkans22/04/2021 13:25:00
Remarks given recently (20 April 2021) by Commissioner Olivér Várhelyi on the first deliveries of EU funded vaccines for the Western Balkans.
Opening remarks by President von der Leyen at the civil society consultation ahead of the Global Health Summit21/04/2021 12:38:00
Opening remarks given yesterday by President von der Leyen at the civil society consultation ahead of the Global Health Summit.
Road safety: 4,000 fewer people lost their lives on EU roads in 2020 as death rate falls to all-time low21/04/2021 11:33:00
The European Commission yesterday published preliminary figures on road fatalities for 2020. An estimated 18,800 people were killed in a road crash last year, an unprecedented annual fall of 17% on 2019.
The European Commission and Austria secure COVID-19 vaccines for the Western Balkans21/04/2021 10:38:00
The European Commission and Austria yesterday announced the conclusion of agreements for the delivery of COVID-19 vaccines for the Western Balkans.
New Commission Knowledge Centre on Earth Observation to further strengthen evidence-based policymaking21/04/2021 09:25:00
The Commission has launched a Knowledge Centre on Earth Observation, to maximise the use of knowledge generated from Earth Observation, in particular from the European Copernicus Programme, in EU policymaking.
EU launches €100 million humanitarian initiative to support COVID-19 vaccination campaigns in Africa20/04/2021 16:38:00
Today, Commissioner for Crisis Management, Janez Lenarčič, will visit the Africa Centres for Disease control and Prevention (Africa CDC) in Addis Ababa.
Justice, rights and values: Council adopts programmes of up to €1.8 billion for 2021-202720/04/2021 15:25:00
The Council yesterday adopted the two programmes which constitute the EU justice, rights and values fund as part of the EU financial framework for 2021-2027.
State aid: Commission adopts revised Regional Aid Guidelines20/04/2021 14:33:00
The European Commission has adopted revised EU guidelines on regional State aid (the “Regional Aid Guidelines”), setting out the rules under which Member States can grant State aid to companies to support the economic development of disadvantaged areas in the EU, while ensuring a level playing field between Member States.
Council adopts position on €14.8 billion EU space programme for 2021-202720/04/2021 13:25:00
The Council yesterday adopted its first reading position on the proposed regulation establishing the EU space programme (“the programme”) for the years 2021 to 2027.
Conference on the Future of Europe: launch of the multilingual digital platform20/04/2021 11:25:00
The Executive Board of the Conference on the Future of Europe, comprising representatives from the European Parliament, the Council of the European Union and the European Commission, is launching the multilingual digital platform for the Conference on the Future of Europe inviting all EU citizens to contribute to shaping their own future and that of Europe as a whole.